Skip to content
MenuOpen navigation menu

Real moms, real GLP-1 talk

Retatrutide: What I Want Moms to Know Right Now

Retatrutide trial results, why it is still not FDA-approved as of November 2026, and why the compounded or research-peptide versions sold online are not legitimate.

Written by — editorial research, not medical advice
On this page

The short answer

Retatrutide is a weekly injection from Eli Lilly that acts on three hormone receptors at once: GIP, GLP-1 and glucagon. In its large trials people lost more weight on average than in the trials behind today's approved shots. As of November 21, 2026, it is not approved by the FDA, and Lilly says no regulator anywhere has approved it4. Anything sold to you as retatrutide right now is not a legitimate product.

Why I went looking

Retatrutide keeps turning up in mom forums and social feeds, often with a photo of a vial and a price attached. I wanted to know what the trials actually showed and whether any of those offers could be real. I read the published trial papers, Lilly's own statement and the FDA's page, and I left the social media posts alone.

What the trials showed

The first paper I read was the phase 2 trial in the New England Journal of Medicine in 2023. It followed 338 adults for 48 weeks, and those on the top 12 mg dose lost an average of 24.2% of their body weight, against 2.1% on placebo1. Stomach side effects rose with the dose, and heart rate went up before settling back down.

Then came the bigger phase 3 trials, the ones regulators look at. These are the published numbers I found as of today:

TrialWho was in itLengthAverage weight changePlacebo
TRIUMPH-1 (NEJM, 2026)2,339 adults with obesity, no diabetes80 weeks−17.6% (4 mg), −23.7% (9 mg), −25.0% (12 mg)−3.9%
TRIUMPH-2 (Lancet, 2026)1,152 adults with obesity and type 2 diabetes80 weeks−11.9% (4 mg), −16.8% (9 mg), −18.8% (12 mg)−5.1%

Sources: TRIUMPH-12 and TRIUMPH-23.

You may see a bigger figure, around 28%, in headlines. That comes from a company analysis that counts only people who stayed on the drug; the journal numbers above count everyone who was randomized, which is the more conservative way to read it. I would also not line these up against Zepbound or Wegovy trial results and call a winner. The same caution I used comparing Zepbound with Wegovy applies here: different trials, different people, different lengths. Lilly is running a head-to-head trial against tirzepatide, and that is the result I would wait for.

Side effects so far

The pattern looks familiar: nausea, diarrhea, vomiting and constipation, mostly early and dose-related. In TRIUMPH-2, nausea hit up to 28% of people on retatrutide versus 8% on placebo, and 4% to 12% stopped because of side effects versus 5% on placebo3. If the familiar stomach symptoms worry you on a drug you already take, the side-effect guide I keep covers what to watch for. One thing that stood out to me was dysesthesia, an odd skin sensation, reported in 4% to 7% of people on retatrutide against 1% on placebo. None of that is a reason to try an unapproved version early.

Pregnancy, breastfeeding and birth control

This is the part I would underline for any mom. There is no FDA label for retatrutide, so there is no pregnancy section, no breastfeeding section and no contraception instruction to read. Every approved drug in this family says to stop once a pregnancy is recognized, and the tirzepatide label adds a backup-method rule for birth-control pills after starting and after each dose increase. Retatrutide shares the GIP and GLP-1 actions that sit behind the Zepbound birth-control warning, but nobody has published what it does to the pill. I would treat "unknown" as exactly that.

Why the online versions are not legitimate

This is where I got the clearest answers. The FDA says retatrutide cannot be used in compounding under federal law, because it is not a component of any approved drug and has not been found safe and effective for any condition5. The agency says it has warned telehealth companies for marketing it and sellers for labeling it "for research purposes" or "not for human consumption" while shipping it with dosing instructions.

One August 2026 warning letter lists a product called "Retatrutide (GLP-3 RT)" as an unapproved new drug, and says the "research use only" label did not change that6. Lilly's own wording is blunter: anyone purporting to sell retatrutide to consumers is breaking the law4. That is different from the debate over compounded semaglutide and tirzepatide, where an approved drug exists and pharmacies work under specific rules. Here there is no approved drug at all, so nobody can tell you what is actually in the vial, how pure it is or whether the dose on the label is real.

What I would do instead

If retatrutide is the reason you are thinking about treatment, the medicines you can get today already have labels, dose ladders and safety data. A brand-name prescriber such as LifeMD or Sesame Care can talk through Zepbound or Wegovy, and the daily pill Foundayo is another option with a published label. I would compare those on cost and routine, and look at the tirzepatide dose ladder to see what the first months actually involve. Every one of them has a label I can read before I decide.

I would keep an eye on the FDA's decision when it comes. If you already bought something sold as retatrutide and you feel unwell after using it, stop and call a doctor or poison control, and keep the packaging to show them.

Frequently asked questions

Is retatrutide FDA-approved?

No. As of November 21, 2026, retatrutide is an investigational drug. Eli Lilly says it has not been approved by the FDA or any regulator anywhere in the world, so there is no prescribing label, no approved dose and no legal way to buy it outside a clinical trial.

How much weight did people lose on retatrutide?

In the published phase 3 TRIUMPH-1 trial of 2,339 adults without diabetes, average weight change at 80 weeks was −17.6% on 4 mg, −23.7% on 9 mg and −25.0% on 12 mg, against −3.9% on placebo. In TRIUMPH-2, among adults with type 2 diabetes, it was −11.9% to −18.8% against −5.1%. These were separate trials, not head-to-head comparisons with Zepbound or Wegovy.

Can a pharmacy compound retatrutide?

No. The FDA states that retatrutide cannot be used in compounding under federal law, because it is not a component of any FDA-approved drug and has not been found safe and effective for any condition. Products sold as compounded or research-use retatrutide are unapproved drugs of unknown content and quality.

Is retatrutide safe during pregnancy or breastfeeding?

Nobody knows. There is no approved label with pregnancy, breastfeeding or contraception guidance. Approved drugs in the same family say to stop once pregnancy is recognized, and tirzepatide's label warns that it can reduce how well birth-control pills work. If you are pregnant, breastfeeding or trying to conceive, talk with your clinician before any GLP-1 medicine.

References

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/37366315/
  2. Jastreboff AM, Kaplan LM, Davies MJ, et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/42814954/
  3. Bellido V, et al. (2026). Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.. Lancet. https://pubmed.ncbi.nlm.nih.gov/42810372/
  4. Eli Lilly and Company (2026). Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial (press release, October 28, 2026; FAQ on legal sale and About retatrutide). PR Newswire. https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html
  5. U.S. Food and Drug Administration (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss (section: Retatrutide and cagrilintide cannot be used in compounding). FDA. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  6. U.S. Food and Drug Administration, CDER Office of Unapproved Drugs and Labeling Compliance (2026). Warning letter to TXP Innovations LLC dba Tex Peptides (MARCS-CMS 735067), August 24, 2026. FDA. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/txp-innovations-llc-dba-tex-peptides-735067-08242026

One mom to another, not a doctor: everything here is for learning and figuring out your options, not medical advice, a diagnosis, or a plan for your body. Pregnancy planning and breastfeeding need advice for the exact medicine and formulation. Before you start, stop, or change anything, talk it through with a clinician who actually knows your history.